• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Management of Type 2 Diabetes Complications, Comorbidities Focus of AACE 2022 Guideline Update


Recommendations for the management of comorbidities and complications associated with type 2 diabetes (T2D) comprise a substantial section of new clinical guidelines from the American Association of Clinical Endocrinology (AACE), released in September.

Patient Care® recently asked AACE president Sethu Reddy, MD, MBA, to highlight for primary care clinicians which updates in this comprehensive section may be most likely to affect day-to-day clinical management of their patients with T2D.

In the conversation below Reddy discusses making T2D medication choices based on prominent comorbidities, the role of obesity management in reducing risk for or impact of comorbidities and complications, newer agents approved to treat hypercholesterolemia, and novel agents proving effective against chronic kidney disease.

For more conversations with Dr Reddy:

AACE President Sethu Reddy, MD, Highlights Updated 2022 Diabetes Guidelines for Primary Care

S Sethu K Reddy, MD, MBA, is the president of the American Association of Clinical Endocrinology and senior assocate dean of clinical research at Central Michigan University (CMU) College of Medicine, in Mount Pleasant, MI. Before joining CMU Reddy worked with the Cleveland Clinic in their endocrinology, diabetes and metabolism department for nearly 30 years.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.